Active Surveillance for Favorable-risk Prostate Cancer: Is There a Greater Psychological Impact Than Previously Thought? A Systematic, Mixed Studies Literature Review
Overview
Psychology
Affiliations
Objective: Active surveillance (AS) allows men with favorable-risk prostate cancer to avoid or postpone active treatment and hence spares potential adverse effects for a significant proportion of these patients. Active surveillance may create an additional emotional burden for these patients. The aim of the review was to determine the psychological impact of AS to inform future study in this area and to provide recommendations for clinical practice.
Methods: Studies were identified through database searching from inception to September 2015. Quantitative or qualitative noninterventional studies published in English that assessed the psychological impact of AS were included. The Mixed Methods Appraisal Tool was used to assess methodological quality.
Results: Twenty-three papers were included (20 quantitative and 3 qualitative). Quantitatively, the majority of patients do not report psychological difficulties; however, when appropriateness of study design is considered, the conclusion that AS has minimal impact on well-being may not be accurate. This is due to small sample sizes, inappropriately timed baseline, and inappropriate/lack of comparison groups. In addition, a mismatch in outcome was noted between the outcome of quantitative and qualitative studies in uncertainty, with qualitative studies indicating a greater psychological impact.
Conclusions: Because of methodological concerns, many quantitative studies may not provide a true account of the burden of AS. Further mixed-methods studies are necessary to address the limitations highlighted and to provide clarity on the impact of AS. Practitioners should be aware that despite findings of previous reviews, patients may require additional emotional support.
Cincidda C, Pizzoli S, Oliveri S, Guiddi P, Pravettoni G Front Med (Lausanne). 2024; 11:1356385.
PMID: 38646557 PMC: 11027503. DOI: 10.3389/fmed.2024.1356385.
Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review.
Bernardino R, Sayyid R, Leao R, Zlotta A, van der Kwast T, Klotz L Can Urol Assoc J. 2024; 18(4):135-144.
PMID: 38381936 PMC: 11034964. DOI: 10.5489/cuaj.8539.
Kang D, Boule N, Field C, Fairey A, Courneya K Int J Behav Nutr Phys Act. 2022; 19(1):126.
PMID: 36175907 PMC: 9524100. DOI: 10.1186/s12966-022-01365-2.
Eymech O, Brunckhorst O, Fox L, Jawaid A, Van Hemelrijck M, Stewart R Support Care Cancer. 2022; 30(6):5459-5468.
PMID: 35304633 PMC: 8933126. DOI: 10.1007/s00520-022-06976-w.
Impact of lifestyle in prostate cancer patients. What should we do?.
Garcia-Perdomo H, Gomez-Ospina J, Chaves-Medina M, Sierra J, Autran Gomez A, Rivas J Int Braz J Urol. 2021; 48(2):244-262.
PMID: 34472770 PMC: 8932020. DOI: 10.1590/S1677-5538.IBJU.2021.0297.